The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.

Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T.Arthritis Rheum. 2004 Mar;50(3):794-804. doi: 10.1002/art.20206